Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Heart Failure 2Cardiotoxicity 2Neoplasms 1

Interventions

Trastuzumab 2Ivabradine 2Exercise 2Echocardiography 2Bisoprolol 2salicylhydroxamic acid 1sacubitril and valsartan sodium hydrate drug combination 1mitoquinone 1epicatechin gallate 1dapagliflozin 1candesartan 1Trimetazidine 1Therapeutics 1Surveys and Questionnaires 1Spironolactone 1Silymarin 1Secondary Prevention 1Restraint, Physical 1Ramipril 1Radiotherapy 1Perindopril 1Neoadjuvant Therapy 1Nebivolol 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Fluorouracil 1Epirubicin 1Docetaxel 1Cyclophosphamide 1Cisplatin 1Carvedilol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Cardiotoxicity × Ivabradine × Clear all
NCT04030546 2019-12-18

Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

Vilnius University

Phase 3 Unknown
128 enrolled

Heart Failure, Cardiotoxicity

NCT03650205 2019-04-02

IPAC

University of Sao Paulo

Phase NA Unknown
160 enrolled

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡